Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and who are about to undergo transplantation. Safety and efficacy have been assessed in studies of patients < or = 21 years old at initial diagnosis.